pharma · Hereditary Angioedema · Influenza · BCRX
Biocryst
Biocryst is a pharma organization headquartered in München, DE. It trades on NYSE under ticker BCRX. Primary therapeutic focus areas include Hereditary Angioedema, Influenza, Paroxysmal Nocturnal Hemoglobinuria, Paroxysm
München, DE HQ
1986 Founded
6 Employees
Public company Type
BCRX · NYSE Ticker
Company details
- Status
- Public
- HQ
- München, DE
- Founded
- 1986
- Employees
- 6
- Programs
- 37
- Drugs
- 17
- Patents
- 72
Eculizumab
Phase 2 · small molecule · Paroxysmal Nocturnal Hemoglobinuria (PNH)
Eculizumab for Paroxysmal Nocturnal Hemoglobinuria (PNH) is a Phase 2 program (small_molecule) at Biocryst with 1 ClinicalTrials.gov record(s).
Internal code BCX9930-202
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Biocryst
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Paroxysmal Nocturnal Hemoglobinuria (PNH)
- Status
- terminated
- Trials
- 1